{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:41:27Z","timestamp":1770752487648,"version":"3.50.0"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CEOR"],"DOI":"10.2147\/ceor.s171560","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T22:22:51Z","timestamp":1535581371000},"page":"477-491","source":"Crossref","is-referenced-by-count":9,"title":["Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative"],"prefix":"10.2147","volume":"Volume 10","author":[{"given":"Giorgio Lorenzo","family":"Colombo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Di Matteo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6304-9977","authenticated-orcid":true,"given":"Chiara","family":"Martinotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen M","family":"Jugl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praveen","family":"Gunda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9848-0684","authenticated-orcid":true,"given":"Mariantonietta","family":"Naclerio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4571-654X","authenticated-orcid":true,"given":"Giacomo Matteo","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,8]]},"container-title":["ClinicoEconomics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=44020","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=44020","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T22:22:51Z","timestamp":1535581371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/budget-impact-model-of-secukinumab-for-the-treatment-of-moderate-to-se-peer-reviewed-article-CEOR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/ceor.s171560","relation":{},"ISSN":["1178-6981"],"issn-type":[{"value":"1178-6981","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}